论文部分内容阅读
目的研究联合检测血浆骨桥蛋白(OPN)和细胞间黏附分子-1(ICAM-1)表达水平在预测原发性肝细胞癌(HCC)患者术后转移复发以及生存中的临床应用价值。方法应用酶联免疫吸附试验(ELISA)检测75例HCC患者术前血浆中OPN和ICAM-1的浓度,分析其表达水平与患者术后复发及预后的关系。结果OPN和ICAM-1在所有75例HCC患者外周血中均有表达。有HCC复发患者的血浆OPN和ICAM-1表达水平明显高于无复发患者(OPN分别为210.40ng/ml和154.86ng/ml,P=0.001;ICAM-1分别为1011.23ng/ml和747.49ng/ml,P=0.027)。OPN高表达组患者的平均生存时间(OS)和无瘤生存时间(DFS)较无复发组患者明显缩短(OS:625d∶808d,P=0.0006;DFS:433d∶674d,P=0.0003);ICAM-1高表达组患者的平均OS和DFS时间也较低表达组患者明显缩短(651d和794d,P=0.0269;489d和642d,P=0.0248)。OPN和ICAM-1两者水平均高和均低的患者术后2年复发率分别为87.50%和28.00%(P<0.001)、2年生存率分别为37.50%和88.00%(P=0.0001)、2年无瘤生存率分别为12.50%和76.00%(P=0.0001)。结论血浆OPN与ICAM-1和肝癌患者术后复发及预后有关;联合应用血浆OPN和ICAM-1可以准确筛选出具有较高和较低复发及预后风险的患者。
Objective To investigate the clinical value of combined detection of OPN and ICAM-1 in predicting the metastasis, recurrence and survival of patients with primary hepatocellular carcinoma (HCC). Methods Serum levels of OPN and ICAM-1 were measured by enzyme-linked immunosorbent assay (ELISA) in 75 patients with HCC. The relationship between the expression of OPN and ICAM-1 in patients with HCC and the recurrence and prognosis was analyzed. Results OPN and ICAM-1 were expressed in peripheral blood of all 75 patients with HCC. The levels of OPN and ICAM-1 in patients with recurrence of HCC were significantly higher than those without recurrence (OPN was 210.40ng / ml and 154.86ng / ml respectively, P = 0.001; ICAM-1 was 1011.23ng / ml and 747.49ng / ml, P = 0.027). The mean survival time (OS) and disease-free survival time (DFS) of patients with OPN overexpression were significantly shorter than those without recurrence (OS: 625d: 808d, P = 0.0006; DFS: 433d: 6744d, P = 0.0003) -1 patients with high-expression group had significantly shorter OS and lower DFS time (651d and 794d, P = 0.0269; 489d and 642d, P = 0.0248). The 2-year recurrence rates of patients with both high and low OPN and ICAM-1 levels were 87.50% and 28.00% (P <0.001), respectively, and the 2-year survival rates were 37.50% and 88.00% The 2-year disease-free survival rates were 12.50% and 76.00%, respectively (P = 0.0001). Conclusions Plasma OPN is associated with postoperative recurrence and prognosis of patients with ICAM-1 and HCC. Combined use of plasma OPN and ICAM-1 can accurately screen out patients with higher and lower risk of recurrence and prognosis.